RS51076B - Stabilizovani superzasićeni tvrdi rastvori steroidnih lekova - Google Patents

Stabilizovani superzasićeni tvrdi rastvori steroidnih lekova

Info

Publication number
RS51076B
RS51076B RSP-2009/0508A RSP20090508A RS51076B RS 51076 B RS51076 B RS 51076B RS P20090508 A RSP20090508 A RS P20090508A RS 51076 B RS51076 B RS 51076B
Authority
RS
Serbia
Prior art keywords
solid solutions
supersaturated solid
steroidal drugs
stabilised
stabilised supersaturated
Prior art date
Application number
RSP-2009/0508A
Other languages
English (en)
Inventor
Adrian Funke
Torsten Wagner
Ralph Lipp
Original Assignee
Bayer Schering Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928105&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51076(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Aktiengesellschaft filed Critical Bayer Schering Pharma Aktiengesellschaft
Publication of RS51076B publication Critical patent/RS51076B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Praškasta kompozicija, naznačena time, da sadrži steroidni molekul; i amorfnu siliku koja poseduje specifičnu površinu od najmanje 250 m2/g; gde je steroidni molekul rastvoren u rastvaraču apsorbovanom na površinu amorfne silike i gde je steroidni molekul prisutan u rastvaraču u superzasićenoj koncentraciji.Prijava sadrži još 12 patentnih zahteva.
RSP-2009/0508A 2004-03-10 2005-03-10 Stabilizovani superzasićeni tvrdi rastvori steroidnih lekova RS51076B (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55133004P 2004-03-10 2004-03-10
EP04075714 2004-03-10
PCT/IB2005/000748 WO2005087199A2 (en) 2004-03-10 2005-03-10 Stabilised supersaturated solid solutions of steroidal drugs

Publications (1)

Publication Number Publication Date
RS51076B true RS51076B (sr) 2010-10-31

Family

ID=34928105

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2009/0508A RS51076B (sr) 2004-03-10 2005-03-10 Stabilizovani superzasićeni tvrdi rastvori steroidnih lekova

Country Status (33)

Country Link
US (1) US8715735B2 (sr)
EP (2) EP1765290B1 (sr)
JP (1) JP5006185B2 (sr)
KR (1) KR101210695B1 (sr)
CN (1) CN1984644B (sr)
AR (1) AR048500A1 (sr)
AT (1) ATE442131T1 (sr)
AU (1) AU2005221403B8 (sr)
BR (1) BRPI0507342A (sr)
CA (1) CA2558582C (sr)
CR (1) CR8630A (sr)
DE (1) DE602005016551D1 (sr)
DK (1) DK1765290T3 (sr)
EA (1) EA012746B1 (sr)
EC (1) ECSP066902A (sr)
ES (2) ES2332229T3 (sr)
GT (1) GT200500045A (sr)
HK (1) HK1103660A1 (sr)
HR (1) HRP20090614T1 (sr)
IL (1) IL177894A0 (sr)
MY (1) MY142989A (sr)
NO (1) NO20064473L (sr)
NZ (1) NZ549793A (sr)
PA (1) PA8626101A1 (sr)
PE (1) PE20060016A1 (sr)
PL (1) PL1765290T3 (sr)
PT (1) PT1765290E (sr)
RS (1) RS51076B (sr)
SI (1) SI1765290T1 (sr)
SV (1) SV2005002044A (sr)
TW (1) TWI345986B (sr)
UY (1) UY28803A1 (sr)
WO (1) WO2005087199A2 (sr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
CA2612456C (en) * 2005-06-16 2017-06-06 Warner Chilcott Company, Inc. Gel compositions for topical administration
CN101237851B (zh) * 2005-06-16 2013-09-18 沃纳奇尔科特有限责任公司 用于***给药的***组合物
CN101484140B (zh) * 2006-05-10 2012-10-03 赢创德固赛有限责任公司 辊压热解制备的二氧化硅在药物组合物中的应用
BRPI0807581A2 (pt) 2007-02-23 2014-07-01 Gilead Science Inc Moduladores de propriedades farmacocinéticas de produtos terapêuticos
JP5600058B2 (ja) * 2007-04-11 2014-10-01 ファーマシューティカル プロダクションズ， インコーポレイテッド メラトニンタブレットならびに調剤及び使用方法
KR20100125309A (ko) * 2008-02-13 2010-11-30 바이엘 쉐링 파마 악티엔게젤샤프트 에스트라디올-함유 약물 전달 시스템
CA2718255C (en) * 2008-03-11 2016-08-23 Aska Pharmaceutical Co., Ltd. Solid dispersion and pharmaceutical composition of the same, and production processes thereof
CN104940937A (zh) 2008-05-02 2015-09-30 吉里德科学公司 固体载体颗粒在改善药物制剂加工性中的应用
WO2009138224A1 (en) * 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone
EP2381946A4 (en) * 2008-10-10 2012-08-08 Teva Womens Health Inc METHOD FOR THE TREATMENT OF VASOMOTOR SYMPTOMS IN CASE RATED PROSTATE RAY PATIENTS WITH LOW-DOSED CYPROTERONE ACETATE
CA2752805A1 (en) * 2009-02-18 2010-08-26 Bayer Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
CN102413813B (zh) * 2009-03-24 2014-11-12 Adds制药有限责任公司 用于口服递送的稳定化的溶解性增强的制剂
FR2947178B1 (fr) * 2009-06-29 2012-07-06 Effik Composition pharmaceutique a base de progesterone micronisee et ses utilisations
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012120365A1 (en) 2011-03-07 2012-09-13 Aurobindo Pharma Limited Stable pharmaceutical composition comprising ethinyl estradiol
US20140178479A1 (en) * 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10835495B2 (en) 2012-11-14 2020-11-17 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20140303128A1 (en) * 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
CA2992923C (en) 2014-07-21 2021-06-29 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal and sublingual administration of cannabinoids
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
CN106109420B (zh) * 2016-08-11 2018-07-06 吴启旸 依普利酮固体分散体及其制剂
AU2018222468B2 (en) * 2017-02-14 2023-05-11 Dsm Ip Assets B.V. Water dispersible formulations
EA201991798A1 (ru) * 2017-02-14 2019-12-30 ДСМ АйПи АССЕТС Б.В. Стабильные при хранении составы
CN110013467B (zh) * 2018-01-10 2021-09-17 上海汉都医药科技有限公司 一种固体微粒及其制备方法和含其的药物组合物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA72698B (en) * 1972-02-03 1973-09-26 Liebenberg R W Method of preparing medicinal compositions
US4013785A (en) * 1975-03-21 1977-03-22 Bristol-Myers Company Apap tablet containing fumed silica and process for manufacturing same
DE2845326C2 (de) * 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
GB8403359D0 (en) 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
IT1216570B (it) * 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
DE3916112A1 (de) * 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
US5183662A (en) 1990-08-30 1993-02-02 Senju Pharmaceutical Co., Ltd. Controlled drug release composition
EP0492007B1 (en) * 1990-11-29 1995-02-08 F.H. FAULDING & CO. LIMITED Process for producing liquid loaded powders
DE4326240A1 (de) * 1993-08-02 1995-02-09 Schering Ag 15,15-Dialkyl-substituierte Derivate des Estradiols
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
US5800834A (en) 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
KR20000000016A (ko) 1999-02-10 2000-01-15 김일 자동차용번호판부착볼트구조
ATE254464T1 (de) 1999-08-31 2003-12-15 Schering Ag Pharmazeutische kombination von ethinylestradiol und drospirenone als empfängnisverhütendes mittel
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
ATE305789T1 (de) 2000-01-18 2005-10-15 Schering Ag Pharmazeutische kombination aus mikronisiertem drospirenon und einen estrogen für die hormonersatztherapie
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
EA006777B1 (ru) * 2001-06-22 2006-04-28 Пфайзер Продактс Инк. Фармацевтические композиции адсорбатов аморфного лекарственного средства
ITMC20010031U1 (it) 2001-07-05 2003-01-07 Best Raffaello Srl Recipiente di cartone ad uso alimentare, dotato di un tratto anulare superiore asportabile a strappo
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
US7943602B2 (en) 2002-09-05 2011-05-17 Pantarhei Bioscience B.V. Pharmaceutical application of 15- or 16-substituted testosterone analogues
PT1558265E (pt) 2002-11-05 2010-03-22 Bayer Schering Pharma Ag Utilização da drospirenona para o tratamento da hipertensão
DE20217332U1 (de) 2002-11-11 2003-02-27 Brand Factory Swiss Gmbh, Rotkreuz Socke
CA2516096A1 (en) 2003-02-19 2004-09-02 Lifecycle Pharma A/S Use of a silica or silica derivative as a sorption material
FR2851918B1 (fr) * 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
ES2325591T3 (es) 2004-03-10 2009-09-09 Bayer Schering Pharma Aktiengesellschaft Composiciones que comprenden drospirenona dispersada molecularmente.

Also Published As

Publication number Publication date
WO2005087199A2 (en) 2005-09-22
US8715735B2 (en) 2014-05-06
CR8630A (es) 2007-06-06
SI1765290T1 (sl) 2010-01-29
JP5006185B2 (ja) 2012-08-22
JP2007528389A (ja) 2007-10-11
NO20064473L (no) 2006-10-10
CA2558582A1 (en) 2005-09-22
PL1765290T3 (pl) 2010-02-26
PE20060016A1 (es) 2006-02-16
EP2087883A1 (en) 2009-08-12
HK1103660A1 (en) 2007-12-28
CN1984644A (zh) 2007-06-20
TW200600116A (en) 2006-01-01
IL177894A0 (en) 2006-12-31
EA012746B1 (ru) 2009-12-30
HRP20090614T1 (hr) 2009-12-31
ATE442131T1 (de) 2009-09-15
MY142989A (en) 2011-02-14
AU2005221403B8 (en) 2010-01-07
EA200601588A1 (ru) 2007-02-27
EP1765290B1 (en) 2009-09-09
KR101210695B1 (ko) 2012-12-11
AU2005221403A1 (en) 2005-09-22
ECSP066902A (es) 2006-12-20
AR048500A1 (es) 2006-05-03
NZ549793A (en) 2010-06-25
EP1765290A2 (en) 2007-03-28
EP2087883B1 (en) 2012-07-25
ES2332229T3 (es) 2010-01-29
WO2005087199A3 (en) 2009-01-15
PT1765290E (pt) 2009-11-23
PA8626101A1 (es) 2006-07-03
BRPI0507342A (pt) 2007-07-03
TWI345986B (en) 2011-08-01
US20050207990A1 (en) 2005-09-22
CA2558582C (en) 2013-07-16
SV2005002044A (es) 2005-11-04
KR20060132999A (ko) 2006-12-22
WO2005087199A8 (en) 2007-03-29
DE602005016551D1 (de) 2009-10-22
GT200500045A (es) 2005-10-31
DK1765290T3 (da) 2009-11-02
UY28803A1 (es) 2005-10-31
ES2390406T3 (es) 2012-11-12
AU2005221403B2 (en) 2009-12-10
CN1984644B (zh) 2010-12-08

Similar Documents

Publication Publication Date Title
RS51076B (sr) Stabilizovani superzasićeni tvrdi rastvori steroidnih lekova
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
WO2003087094A3 (en) Pyrrolidinium derivatives as antagonists of m3 muscarinic receptors
CR8642A (es) Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos
FR2909284B1 (fr) Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien
BR0210519A (pt) Composições farmacêuticas de adsorvatos de fármaco amorfo
HK1140947A1 (en) Pharmaceuticals compositions of a neuroactive steroid and uses thereof
DE602004007257D1 (de) Hydroxy-diaryl-carbaldehyd- oxim-verbindungen und deren verwendung als oestrogenwirksame substanzen
IS6344A (is) Lyfjasamsetningar sem leiða til aukinna lyfjastyrkja
DK1244401T3 (da) Medikamentdosering af faseændrende formulering
DK1501485T3 (da) Tablet med höjt indhold af aktivt stof
ATE509634T1 (de) Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel
DE60105448D1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
UY29771A1 (es) Nueva forma cristalina
DE60332393D1 (de) Flüssige pharmazeutische zusammensetzung mit pyridonderivaten
ATE401875T1 (de) Pharmazeutische feste dispersionen von modafinil- verbindungen
RS52777B (sr) Terapijski sistem sa trenutnim otpuštanjem za poboljšanu oralnu apsorpciju 7-[(e)-tert-butiloksiiminometil] kamptotecina
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
CL2007003672A1 (es) Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.
ATE267601T1 (de) Pharmazeutische zusammensetzung enthaltend pemetrexed zusammen mit monothioglycerol, l- cystein oder thioglykolsäure
ATE491447T1 (de) Flavonoide und tocotrienole enthaltende zusammensetzungen und deren verwendungen
PE20070529A1 (es) Composicion farmaceutica que contiene azodicarbonamida micronizada y su preparacion
RS51534B (sr) Novi spoj inihbitora sinusoidne if struje i kalcijumskog inhibitora i farmaceutske smeše koje ga sadrže
DE60301261D1 (de) Pharmazeutische zusammensetzungen enthaltend 17alpha-furanylester von 17beta-carbothioat androstanderivaten und einen muskarinrezeptorantagonist